Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders

Abstract

Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.

What is claimed is: 
     
         1 . A method of depleting a B-cell population in a subject with excessive B-cell proliferation, which comprises
 (a) administering to said subject a combination of agents, for a time and in therapeutically effective amounts to treat a disease or disorder associated with excessive B-cell proliferation, said combination of agents comprising:
 (i) at least one PI3K-delta selective inhibitor, wherein said PI3K-delta selective inhibitor is a compound of Formula A, a stereoisomer thereof, a pharmaceutically acceptable salt, or solvate, thereof: 
   
       
         
           
           
               
               
           
         
         selected from (RS)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one; or (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one;
 (ii) at least one anti-CD20 antibody or an antigen-binding fragment thereof, and 
 (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor; and 
 
         (b) depleting said B-cells in said B-cell population by promoting apoptosis, promoting cell-cycle arrest, blocking the B-cell receptor (BCR) signaling pathway, or a combination thereof. 
       
     
     
         2 . The method of  claim 1 , wherein said PI3K-delta selective inhibitor is (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one. 
     
     
         3 . The method of  claim 2 , wherein said anti-CD20 antibody is ublituximab or an anti-CD20 antibody that binds to the same epitope as ublituximab. 
     
     
         4 . The method of  claim 3 , wherein said BTK inhibitor is selected from the group consisting of acalabrutinib; GDC-0834; ONO-4059; RN-486; spebrutinib; SNS-062; HM-71224; CGI-560; CGI-1746; CTA-056; CNX-774; BGB-3111; LFM-A13; PCI-45227; dasatinib; ONO-WG-307; JTE-051; AVL-263; AVL-291; AVL-101; TP-4207; PCI-45292; PCI-45466; CG-036806; TAS-5567; PCI-45261; KBP-7536; HCl-1684; PLS-123; BMS-488516; BMS-509744; and HY-11066. 
     
     
         5 . The method of  claim 1 , wherein said hematological malignancy is selected from the group consisting of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma (FL), Waldenstrom's macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), Burkitt's lymphoma, hairy cell leukemia (HCL), and Richter's transformation. 
     
     
         6 . A method of treating chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL) in a subject which comprises
 (a) administering to the subject a combination of agents, for a time and in therapeutically effective amounts to treat said CLL, MZL, SLL or MCL, said combination of agents comprising:
 (i) at least one PI3K-delta selective inhibitor represented by Formula A, a stereoisomer thereof, a pharmaceutically acceptable salt, or solvate, thereof: 
   
       
         
           
           
               
               
           
         
         selected from (RS)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one; or (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one;
 (ii) at least one anti-CD20 antibody or an antigen-binding fragment thereof, and 
 (iii) at least one inhibitor of Bruton's tyrosine kinase (BTK); and 
 
         (b) reducing said subject's baseline disease burden by at least 50% by the first efficacy assessment. 
       
     
     
         7 . The method of  claim 6 , wherein the PI3K-delta inhibitor is (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The method of  claim 7 , wherein the P13K-delta inhibitor is administered at a dosage from: about 200 mg to about 1200 mg, about 400 mg to about 1000 mg, about 400 mg to about 800 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, or about 1200 mg. 
     
     
         9 . The method of  claim 6 , wherein the PI3K-delta inhibitor is (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one p-toluenesulfonic acid salt (TGR-1202). 
     
     
         10 . The method of  claim 9 , wherein TGR-1202 is administered at a dose from (a) about 400 mg to about 1200 mg per day or (b) about 800 mg per day. 
     
     
         11 . The method of  claim 6 , wherein said anti-CD20 antibody is ublituximab or an anti-CD20 antibody that binds to the same epitope as ublituximab. 
     
     
         12 . The method of  claim 11 , wherein said anti-CD20 antibody is ublituximab. 
     
     
         13 . The method of  claim 12 , wherein ublituximab is administered at a dose from: about 450 mg to about 1200 mg, about 600 to about 1200 mg, about 600 to about 1000 mg, about 600 to about 900 mg, about 600 mg, about 700 mg, about 800 mg, or about 900 mg about once every 1 to 9 weeks, about once every week, about twice every week, about once every 2 weeks, about once every 3 weeks, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 week, or about once every 9 weeks. 
     
     
         14 . The method of  claim 13 , wherein ublituximab is administered at a dose of about 900 mg. 
     
     
         15 . The method of  claim 6 , wherein the BTK inhibitor is acalabrutinib; GDC-0834; ONO-4059; RN-486; spebrutinib; SNS-062; HM-71224; CGI-560; CGI-1746; CTA-056; CNX-774; BGB-3111; LFM-A13; PCI-45227; dasatinib; ONO-WG-307; JTE-051; AVL-263; AVL-291; AVL-101; TP-4207; PCI-45292; PCI-45466; CG-036806; TAS-5567; PCI-45261; KBP-7536; HCl-1684; PLS-123; BMS-488516; BMS-509744; and HY-11066. 
     
     
         16 . The method of  claim 6 , wherein said CLL, MZL, SLL or MCL overexpresses CD20, is refractory to chemotherapy or has relapsed. 
     
     
         17 . The method of  claim 16 , wherein the CLL, MZL, SLL or MCL is refractory to an anti-CD20 antibody, a P13K-delta inhibitor, or a BTK inhibitor. 
     
     
         18 . The method of  claim 6 , wherein said combination of agents i, ii, and iii are administered separately and/or sequentially. 
     
     
         19 . The method of  claim 6 , wherein said agents i and iii are administered simultaneously or sequentially once a day, and, optionally, are contained in the same pharmaceutical composition. 
     
     
         20 . The method of  claim 6 , wherein step (b) reduces disease burden by at least 75%. 
     
     
         21 . A method for treating chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL) in a human subject which comprises,
 (a) administering to said subject a combination of agents, in therapeutically effective amounts to treat said CLL, MZL, SLL or MCL, said combination of agents comprising:
 (i) TGR-1202; 
 (ii) ublituximab; and 
 (iii) a Bruton's tyrosine kinase (BTK) inhibitor; and 
   (b) reducing said subject's baseline disease burden by at least 50% by the first efficacy assessment.   
     
     
         22 . The method of  claim 21 , wherein step (b) reduces disease burden by at least 75%. 
     
     
         23 . A kit comprising:
 (i) at least one PI3K-delta selective inhibitor represented by Formula A, a stereoisomer thereof, a pharmaceutically acceptable salt, or solvate, thereof:   
       
         
           
           
               
               
           
         
       
       selected from (RS)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one; or (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one;
 (ii) at least one anti-CD20 antibody or an antigen-binding fragment thereof, wherein said anti-CD20 antibody is ublituximab or an anti-CD20 antibody that binds to the same epitope as ublituximab; and 
 (iii) at least one inhibitor of Bruton's tyrosine kinase (BTK). 
 
     
     
         24 . The kit of  claim 23 , wherein agent (i) is (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 
     
     
         25 . The kit of  claim 24 , wherein agent (ii) is ublituximab. 
     
     
         26 . The kit of  claim 24 , wherein agent (iii) is ibrutinib or acalabrutinib. 
     
     
         27 . The kit of  claim 26 , wherein agent (i) is TGR-1202.